Get the Stockscreener App
11.34
4.30%
-0.51
After Hours:
11.30
-0.04
-0.35%
Lyra Therapeutics Inc stock is traded at $11.34, with a volume of 217.33K.
It is down -4.30% in the last 24 hours and up +140.25% over the past month.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
See More
Previous Close:
$11.85
Open:
$11.49
24h Volume:
217.33K
Relative Volume:
0.35
Market Cap:
$32.18M
Revenue:
$1.47M
Net Income/Loss:
$-97.61M
P/E Ratio:
-7.6107
EPS:
-1.49
Net Cash Flow:
$-80.90M
1W Performance:
-53.29%
1M Performance:
+140.25%
6M Performance:
+24.21%
1Y Performance:
-26.86%
1-Day Range:
$10.98
$12.50
1-Week Range:
$10.98
$23.83
52-Week Range:
$3.8101
$37.50
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
Lyra Therapeutics Inc
Sector
Industry
Phone
617-373-4600
Address
480 ARSENAL WAY, WATERTOWN, MA
Compare LYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
11.34 | 32.18M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Downgrade | BofA Securities | Buy → Underperform |
| May-07-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-07-24 | Downgrade | Jefferies | Buy → Hold |
| May-06-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-23 | Resumed | BTIG Research | Buy |
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Stake Lessened by Two Sigma Investments LP - Defense World
HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World
Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why - sharewise
H.C. Wainwright lifts Lyra Therapeutics stock target to $16 By Investing.com - Investing.com Canada
Lyra Therapeutics (LYRA) Price Target Raised by HC Wainwright & Co. | LYRA Stock News - GuruFocus
H.C. Wainwright Ups Target Price for Lyra Therapeutics (LYRA) to $16 | LYRA Stock News - GuruFocus
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Sold by Two Sigma Advisers LP - Defense World
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success - MSN
Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win - insights.citeline.com
Northern Trust Corp Has $59,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Study: LYR-210 Shows Promise in Chronic Rhinosinusitis With Nasal Polyps - Pharmacy Times
BNP Paribas Financial Markets Makes New Investment in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Best Biotech Stocks To Watch Now – June 2nd - Defense World
Biotech Triumphs: Lyra, Vera, And US Gold Shine Bright - Finimize
Lyra Therapeutics stock hits 52-week high at $28.66 By Investing.com - Investing.com Canada
Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled - Asianet Newsable
Lyra Therapeutics reports positive phase 3 trial results for CRS treatment By Investing.com - Investing.com South Africa
Applied Digital Corp, Meta Platforms, Alphabet, Lyra Therapeutics, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled By Stocktwits - Investing.com India
Redemption for Lyra as second phase III rhinosinusitis trial hits goal - BioWorld MedTech
One year after massive layoffs, Lyra stock soars 400% on trial win - The Business Journals
Lyra Therapeutics (LYRA) Surges 376% on Positive Phase 3 Trial R - GuruFocus
Lyra Therapeutics (LYRA) Surges 376% on Positive Phase 3 Trial Results - GuruFocus
Microcap Lyra Therapeutics surges 376% on phase 3 rhinosinusitis data - Seeking Alpha
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May - Benzinga
Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win - Yahoo Finance
Lyra Therapeutics Spikes 417% as LYR-210 Redefines CRS Therapy - Wall Street Pit
LYR-210 Nasal Implant for CRS Brings Symptom Relief in Phase 3 ENLIGHTEN 2 - HCPLive
Lyra Therapeutics says ENLIGHTEN 2 trial of LYR-210 met primary endpoint - TipRanks
Lyra Therapeutics Soars on Breakthrough Nasal Implant Results - RagingBull
Lyra Therapeutics Shares Soar 603.25% to $34.67 on LYR-210 Trial Success - Trading Pedia
Transcript : Lyra Therapeutics, Inc.Special Call - marketscreener.com
Lyra Therapeutics stock hits 52-week high at $28.66 - Investing.com
This penny stock just spiked 550% in a day; Time to buy? - Finbold
Lyra Therapeutics Stock (LYRA) Rockets 530% on Phase 3 Trial Results - TipRanks
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210 - marketscreener.com
Lyra Says Phase 3 Trial of Nasal Implant for Chronic Rhinosinusitis Meets Endpoints - marketscreener.com
Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga
Lyra Therapeutics Announces Positive Phase 3 Trial Results - TipRanks
LYRA Sees Promising Results in ENLIGHTEN 2 Phase 3 Trial for CRS Treatment | LYRA Stock News - GuruFocus
Lyra Therapeutics reports positive phase 3 trial results for CRS treatment - Investing.com Australia
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket - Benzinga
Lyra Therapeutics stock soars on positive Phase 3 trial results By Investing.com - Investing.com Canada
Lyra Therapeutics stock soars on positive Phase 3 trial results - Investing.com
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewswire
Lyra Therapeutics (NASDAQ:LYRA) Stock Rating Upgraded by Wall Street Zen - Defense World
Lyra Therapeutics (LYRA) Trading Suspended Awaiting News Update - GuruFocus
Lyra Therapeutics (LYRA) Trading Suspended Awaiting News Update | LYRA Stock News - GuruFocus
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):